Biodexa (NASDAQ:BDRX) stock shot up 70% in morning trading Thursday after the company re-released positive data from a Phase 2 study for its drug eRapa in the treatment of Familial Adenomatous ...

Biodexa Pharmaceuticals shares surge following phase 2 trial results for eRapa, a potential treatment for Familial Adenomatous Polyposis. The study showed a 17% median reduction in polyp burden ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous ...

April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis ...

An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum. FAP is a substantially genetic orphan ...

February 10, 2025. Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis. Underscores unmet need for a therapeutic alternative with the potential to delay or ...

In summary, eRapa appeared safe and well-tolerated with a significant 24% reduction in the total polyp burden at six months compared with baseline (p=0.04) and an overall 83% non-progression rate.

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona Biodexa Pharmaceuticals ...

Among patients who received eRapa 0.5mg daily every other week (cohort 2), 89% were deemed non-progressors, with a median decrease in polyp burden of 29% at 12 months.

Biodexa (BDRX) stock rallied 80% Tuesday following positive Phase 2 data for the company's drug eRapa in the treatment of familial adenomatous polyposis, or FAP. Read more here.

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous ...

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Apr. 26, 2024 8:30 AM ET Biodexa Pharmaceuticals Plc (BDRX) ...